OX40, OX40L and Autoimmunity: a Comprehensive Review

Area of Science:

• Immunology
• Autoimmunity
• Molecular Biology

Background:

• The OX40-OX40L pathway is crucial for T cell co-stimulation and survival.
• OX40 is expressed on T cells, including regulatory T cells (Treg), while OX40L is found on antigen-presenting cells and other immune cells.
• Their interactions are upregulated by pro-inflammatory signals and antigen presentation.

Purpose of the Study:

• To review the expression and function of OX40 and OX40L in health and disease.
• To explore the role of OX40-OX40L interactions in human autoimmune diseases.
• To evaluate the therapeutic potential of targeting this pathway for autoimmunity.

Main Methods:

• Literature review of OX40 and OX40L expression and function.
• Analysis of genetic associations with autoimmune diseases.
• Examination of data from animal models of human diseases.
• Review of clinical trial data for OX40L blockade.

Main Results:

• OX40-OX40L interactions promote T cell effector functions and memory, while potentially reducing regulatory function.
• Genetic variations in TNFRSF4 and TNFSF4 are associated with autoimmunity.
• OX40L blockade may be more effective than OX40 blockade in preclinical models of autoimmunity.
• Early clinical data suggests potential efficacy but also highlights challenges in therapeutic application.

Conclusions:

• The OX40-OX40L pathway is a significant factor in T cell-mediated immunity and autoimmunity.
• Targeting OX40-OX40L interactions, particularly via OX40L blockade, presents a viable therapeutic strategy for autoimmune diseases.
• Further research and clinical trials are needed to optimize the use of OX40-OX40L-directed therapies and mitigate potential adverse effects.